Redmile Group, LLC insider trades

Name: Redmile Group, LLC Form 4 insider trades
Creator: WaveMan
License: https://wave-man.com/terms

Redmile Group, LLC has filed 40 Form 4s with the SEC that we hold, for IGMS (Director, 10% owner), Fate Therapeutics INC (FATE) (Director, 10% owner), AUGX (Director, 10% owner) and Shattuck Labs, Inc. (STTK) (Director, 10% owner), among 13 companies in all. Across all of them we count 9 purchases worth $92.8M and 1 sale worth $757.6K reported on Form 4. In the last 12 months: 2 purchases ($10.2M) and 0 sales ($0). The largest single trade was a purchase of 1,875,000 shares of Absci Corp worth $30.0M, dated 2021-07-26. The first filing on our record is dated 2021-07-28 and the latest 2026-08-07.

IGMS

Director, 10% owner · 11 filings · 2 purchases and sales

Trade date	Code	Shares	Value as filed	Filed
2023-06-29	P, purchase reported on Form 4	80,423	$757.6K	2023-07-03
2023-06-29	S, sale reported on Form 4	80,423	$757.6K	2023-07-03

Fate Therapeutics INC (FATE)

Director, 10% owner · 5 filings · 1 purchase or sale

Trade date	Code	Shares	Value as filed	Filed
2023-12-26	P, purchase reported on Form 4	44,630	$166.0K	2023-12-28

AUGX

Director, 10% owner · 4 filings · 1 purchase or sale

Trade date	Code	Shares	Value as filed	Filed
2021-10-28	P, purchase reported on Form 4	1,625,000	$6.5M	2021-11-01

Shattuck Labs, Inc. (STTK)

Director, 10% owner · 4 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

ADC Therapeutics SA (ADCT)

10% owner · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Absci Corp (ABSI)

Director · 3 filings · 1 purchase or sale

Trade date	Code	Shares	Value as filed	Filed
2021-07-26	P, purchase reported on Form 4	1,875,000	$30.0M	2021-07-28

MDVL

Director, 10% owner · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Zymeworks Inc. (ZYME)

10% owner · 2 filings · 1 purchase or sale

Trade date	Code	Shares	Value as filed	Filed
2022-10-13	P, purchase reported on Form 4	30,481	$153.3K	2022-10-18

Atara Biotherapeutics, Inc. (ATRA)

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Attovia Therapeutics, Inc. (ATTO)

10% owner · 1 filing · 2 purchases and sales

Trade date	Code	Shares	Value as filed	Filed
2026-08-06	P, purchase reported on Form 4	200,000	$3.4M	2026-08-07
2026-08-06	P, purchase reported on Form 4	400,000	$6.8M	2026-08-07

Entrada Therapeutics, Inc. (TRDA)

10% owner · 1 filing · 1 purchase or sale

Trade date	Code	Shares	Value as filed	Filed
2021-11-02	P, purchase reported on Form 4	1,000,000	$20.0M	2021-11-04

Invivyd, Inc. (ADGI)

10% owner · 1 filing · 1 purchase or sale

Trade date	Code	Shares	Value as filed	Filed
2021-08-10	P, purchase reported on Form 4	1,470,000	$25.0M	2021-08-12

SNCE

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1425738) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms